D. A. E. Parolin

A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group

L. Seymour, H. Hirte, W. Miller, 2005, Investigational New Drugs.